Moxifloxacin Ratiopharm (Moxifloxacin)

• Moxifloxacin is a fluoroquinolone antibiotic used to treat bacterial infections of the respiratory tract and skin.
• Community‑acquired pneumonia: effective treatment of bacterial pneumonia in adults.
• Acute bacterial sinusitis: eradicates the causative pathogens and relieves sinus inflammation.
• Acute exacerbations of chronic bronchitis: reduces bacterial load and improves breathing function.
• Acute bacterial COPD exacerbations: helps restore lung function by targeting infecting organisms.
• Skin and soft‑tissue infections: combats a broad range of gram‑positive and gram‑negative bacteria.

• Moxifloxacin exerts a bactericidal effect by binding to bacterial DNA gyrase (topoisomerase II) and topoisomerase IV. This inhibition prevents the supercoiling and separation of DNA strands required for replication and transcription, leading to bacterial cell death. The dual targeting of both enzymes contributes to its broad‑spectrum activity against Gram‑positive, Gram‑negative, and atypical pathogens.

Moxifloxacin may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhea: loose stools, sometimes watery.
• Headache: transient cranial discomfort.
• Dizziness: sensation of light‑headedness.
• Abdominal pain: cramping or discomfort in the stomach area.
• Rash: mild skin irritation or redness.

Serious or Rare Side Effects

• Tendon rupture: sudden pain and loss of function, especially in the Achilles tendon.
• QT interval prolongation: may lead to cardiac arrhythmias.
• Clostridioides difficile infection: severe colitis with watery diarrhea.
• Severe allergic reactions: anaphylaxis, angioedema, or hives.
• Hepatic toxicity: elevated liver enzymes or jaundice.
• Peripheral neuropathy: numbness or tingling in extremities.

• Before prescribing Moxifloxacin, clinicians should evaluate patient‑specific risk factors and monitor for potential complications.
• Assess renal function: adjust therapy if renal impairment is present.
• Avoid in patients with known hypersensitivity to fluoroquinolones: discontinue immediately if allergic reaction occurs.
• Monitor for tendon pain: discontinue if signs of tendonitis or rupture develop.
• Use with caution in patients with QT prolongation: avoid concomitant QT‑prolonging drugs.
• Pregnancy and lactation: safety not established; prescribe only when benefits outweigh risks.
• Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Moxifloxacin can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Antacids containing magnesium or aluminum: reduce absorption of moxifloxacin.
• Warfarin: may increase INR and bleeding risk.
• Corticosteroids: heightened risk of tendon rupture.
• QT‑prolonging agents (e.g., quinidine, macrolides): may cause serious cardiac arrhythmias.
• Theophylline: increased plasma concentrations leading to toxicity.

Moderate Interactions (Monitor Closely)

• Cyclosporine: elevated cyclosporine levels; monitor blood concentrations.
• Insulin or oral hypoglycemics: enhanced hypoglycemic effect; adjust glucose monitoring.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): increased risk of CNS stimulation and seizures.